Search

Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients

Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.

Read more

Publications

The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.

Read more

Stopping tyrosine kinase inhibitors in a very large cohort of European chronic myeloid leukemia patients: results of the EURO-SKI trial

Tyrosine kinase inhibitors (TKI) have substantially improved survival in patients with chronic myeloid leukemia in chronic phase. However, treatment is in clinical practice considered life-long.

Read more

Publications

The publications of the ESLHO networks can be found on the following pages:

EuroFlow publications
EuroMRD publications
EuroClonality publications
The publications from 2023 are also listed below.

Read more

The Clot Thickens

Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).

Read more

SWG Educational Activities

MeetingsEHA SWG EWALL SymposiumLocation and dateThis meeting was held in Frankfurt in June 2023 as part of EHA2023. TopicPersonalized ALL therapy. ChairNicola Gokbuget

Sessions and speakers
B-cell precursor ALL, the Finnish experience (Kimmo Porkka).

Read more

EHA-KCS Hematology Tutorial

EHA is joining the Kazakhstan Cancer Society (KCS) to organize the EHA-KCS Hematology Tutorial on Recent Advances in Lymphoid and Myeloid Malignancies.

Read more

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.

Read more